



‘CIBA EHP Cura’- Phytobiotic formulation for the treatment of EHP in shrimp



- *Enterocytozoon hepatopenaei* (EHP) is a microsporidian pathogen affecting shrimp aquaculture and causing an estimated annual economic loss of US\$ 567.62 M in India.
- The formulation suppresses EHP and *Vibrio* proliferation and supports improved immunity, growth, and survival of shrimp.
- Indian Patent - No. 590796 has been granted for this phytobiotic formulation.
- Extensively field validated in 114 shrimp farms across Tamil Nadu, Andhra Pradesh, West Bengal, Punjab, Gujarat, and Odisha.
- Farm-level evaluation demonstrated approximately 90% improvement in survival, 95% improvement in feed intake, and 80% improvement in growth.
- The technology has been commercialized/licensed to three private partners: Neomeds (Telangana, India), VK Aqua feeds (Andhra Pradesh, India), and Lotus Aqua feeds (Tamil Nadu, India)
- Farmer-friendly oral administration through feed recommended at 40ml/kg of feed for 2 weeks.
- The formulation is suitable for both therapeutic and prophylactic applications
- Technology Readiness Level (TRL) 8-9, reflecting extensive field validation, commercial licensing, and readiness for large-scale adoption in shrimp aquaculture.

CONTACT DETAILS

Director, ICAR-Central Institute of Brackishwater Aquaculture (ICAR-CIBA), Chennai,
mail id- icarciba21@gmail.com | www.ciba.res.in